Viveve Medical, Inc. (VIVE)

NASDAQ: VIVE · IEX Real-Time Price · USD
0.840
+0.040 (5.01%)
At close: Aug 15, 2022 4:00 PM
0.850
+0.010 (1.190%)
After-hours: Aug 15, 2022 7:20 PM EDT
5.01%
Market Cap 8.96M
Revenue (ttm) 6.76M
Net Income (ttm) -28.86M
Shares Out 10.67M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 58,072
Open 0.788
Previous Close 0.800
Day's Range 0.750 - 0.860
52-Week Range 0.590 - 3.080
Beta 0.63
Analysts Buy
Price Target 5.87 (+598.8%)
Earnings Date Aug 11, 2022

About VIVE

Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Mi... [Read more...]

Industry Health Care Equipment & Supplies
Founded 2005
Employees 47
Stock Exchange NASDAQ
Ticker Symbol VIVE
Full Company Profile

Financial Performance

In 2021, Viveve Medical's revenue was $6.43 million, an increase of 17.28% compared to the previous year's $5.48 million. Losses were -$22.03 million, 0.51% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for VIVE stock is "Buy." The 12-month stock price forecast is 5.87, which is an increase of 598.81% from the latest price.

Price Target
$5.87
(598.81% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips PURSUIT clinical trial follow-up visit completion anticipated by year end Conference call to be hosted by Company at...

Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022

ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today anno...

Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan

ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today anno...

Viveve to Participate in H.C. Wainwright Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will p...

Viveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology Report

Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / ...

Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET toda...

Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022

ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2...

Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update

Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treat...

Viveve to Report Full Year 2021 Financial Results and Provide Corporate Update on March 17, 2022

ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021 f...

Viveve to Participate in H.C. Wainwright BIOCONNECT Conference

ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, wil...

Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence

Major milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused o...

Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Total revenue of $1.6M reported for Q3 Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4 ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medica...

Viveve to Host Conference Call on November 11, 2021 to Report Third Quarter Financial Results and Provide Corporate U...

ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter...

Viveve Announces Issuance of New Device and Methods Patent in U.S

Issuance further expands and strengthens Company's intellectual property portfolio ENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focuse...

Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia

Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc. (NASDAQ:VI...

Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive o...

Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for comple...

Viveve to Host Conference Call on August 12, 2021 to Report Second Quarter Financial Results and Provide Corporate Up...

ENGLEWOOD, CO / ACCESSWIRE / August 5, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its second quarter ...

Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent

ENGLEWOOD, CO / ACCESSWIRE / August 3, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Canadian Intellectual Property...

Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure

New code approved by American Medical Association and supported by key medical societies Long-term pathway for potential reimbursement now established for Company's dual-energy noninvasive treatment for...

Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference

ENGLEWOOD, CO / ACCESSWIRE / July 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive office...

Viveve Announces Issuance of New Device and Methods Patent in U.S.

ENGLEWOOD, CO / ACCESSWIRE / June 10, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Tradem...

Viveve Announces Adjournment of Annual Meeting

Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time Company encourages stockholders to cast their votes ENGLEWOOD, CO / ACCESSWIRE / June 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), ...

Recap: Viveve Medical Q1 Earnings

Shares of Viveve Medical (NASDAQ:VIVE) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 2.44% year over year to ($0.80), which missed...

Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update

Pivotal SUI PURSUIT trial enrollment underway and accelerating Total revenue of $1.5M for Q1 including sale of 2,450 consumable treatment tips Strengthened patent portfolio in key Asia Pacific markets E...